SER-252 advances to cohort 2 in phase I-B trial
SER-252, a POZylated apomorphine for advanced Parkinson's, completed cohort 1 and moved to cohort 2 in phase I-B; top-line data are expected in early 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.